Cellectis (NASDAQ:CLLS) Cut to Hold at StockNews.com

StockNews.com downgraded shares of Cellectis (NASDAQ:CLLS) from a buy rating to a hold rating in a research report released on Monday.

Cellectis Stock Performance

CLLS opened at $1.51 on Monday. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a market cap of $83.93 million, a price-to-earnings ratio of -1.16 and a beta of 3.11. The company’s 50 day moving average is $1.37 and its 200 day moving average is $1.59. Cellectis has a 12-month low of $1.10 and a 12-month high of $3.10.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $12.03 million for the quarter, compared to analysts’ expectations of $12.71 million. On average, equities research analysts predict that Cellectis will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Cellectis

Several hedge funds have recently modified their holdings of CLLS. Wells Fargo & Company MN lifted its holdings in shares of Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after buying an additional 12,500 shares in the last quarter. Millennium Management LLC bought a new position in Cellectis during the fourth quarter valued at $962,000. Finally, B Group Inc. bought a new position in Cellectis during the fourth quarter valued at $5,547,000. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.